Abilify is now indicated for the maintenance treatment of manic and mixed episodes associated with bipolar I disorder with or without psychotic features in pediatric patients (aged 10-17) and maintenance treatment of schizophrenia in adolescents (aged 13-17).
In addition, Abilify is also granted an indication for adjunctive therapy to either lithium or valproate for the acute treatment of manic and mixed episodes associated with bipolar I disorder with or without psychotic features in pediatric patients (aged 10-17).
Elliott Sigal, executive vice president, chief scientific officer and president, R&D, Bristol-Myers Squibb, said: “Expanding the clinical uses of an important therapy such as Abilify gives caregivers and pediatric patients with bipolar I disorder or schizophrenia, a new treatment option in their fight against serious disease.”